Looking Beyond the First Day: Building a Sustainable Hemophilia B Plan for School Years Ahead

Content sponsored by Sanofi

For most families, back-to-school means new backpacks and packed lunchboxes. But for children with hemophilia B and their caregivers, it also means preparing for a safe and successful year ahead. New routines, growing independence, and increased participation in school activities may all influence how patients, families, and healthcare professionals (HCPs) approach disease management, making proactive planning essential.

Hemophilia B is a genetic disorder caused by Factor IX (FIX) deficiency that impairs clot formation and can result in recurrent bleeding episodes.¹ As children move through childhood and adolescence, physical, social, and developmental changes may introduce new considerations for maintaining consistent bleed prevention. ²

For pediatric patients, back-to-school planning can be a timely moment to consider how an established treatment approach can offer confidence during changes to everyday life. As children take on new routines, activities, and responsibilities, families and clinicians may look for options that offer trusted bleed protection, demonstrated safety and efficacy, and real-world experience over time. ^2,3 Prophylactic factor replacement therapy, a longstanding cornerstone of hemophilia B management, is often an optimal choice for such patients.²

Thinking Beyond Today: Selecting the Right Treatment for the Right Patient

Selecting prophylactic therapy requires integrating clinical evidence with the patient’s bleeding phenotype, anticipated disease course, lifestyle, and long-term treatment goals.²

Because treatment needs are not static throughout childhood and adolescence, prophylactic regimens should be reassessed periodically to ensure they remain aligned with both clinical objectives and the realities of patients’ daily lives. ² As children become more active and independent, HCPs and families may consider how a treatment plan fits into school schedules, sports, travel, family routines, and increasing responsibility for self-care.

At the same time, treatment fit only represents one part of the conversation. For pediatric patients and their families managing a lifelong condition, HCPs may also consider the depth and duration of evidence supporting a treatment option, including clinical trial experience, long-term follow-up, and real-world use. ^2,3

For some patients, these discussions may include whether the pharmacokinetic profile of an extended half-life (EHL) factor IX replacement therapy better aligns with treatment goals than a more frequent standard half-life (SHL) regimen. ^3,4

SHL and EHL factor IX replacement therapies differ primarily in their pharmacokinetic profiles. SHL therapies replace deficient FIX but have a shorter circulating half-life that often requires more frequent prophylactic dosing. EHL therapies are engineered to prolong FIX activity and may allow longer dosing intervals in appropriate patients. ^3,4

These pharmacokinetic differences represent one of several considerations that may inform individualized prophylactic treatment planning. The biology of FIX may also be part of these conversations. Because FIX distributes beyond the bloodstream into extravascular spaces, HCPs may consider broader clinical outcomes, such as bleed protection, when evaluating treatment options over time.³

Balancing Trusted Protection With Long-Term Treatment Planning

For children growing up with hemophilia B, treatment decisions are often made with both the present and future in mind. HCPs and families may consider how a therapy supports bleed protection today, while also looking at the depth of evidence, clinical familiarity, and real-world experience that can help inform care over time.^2,3

Regular prophylaxis has transformed hemophilia B care by helping reduce bleeding episodes and support joint health.² As children’s schedules, activities, and responsibilities evolve, the practicality of a treatment regimen can also become an important part of long-term planning.

For some families, these discussions may include whether an EHL factor IX replacement therapy better aligns with treatment goals than a more frequent SHL regimen.^3,4 As treatment options continue to expand, clinicians increasingly consider not only whether a therapy provides effective bleed protection today, but also whether it has the depth of evidence and real-world experience to support care through childhood, adolescence, and beyond. ^2,3

ALPROLIX: More Than a Decade of Experience Across Childhood and Beyond

For a lifelong condition like hemophilia B, treatment decisions made in childhood can shape care for years to come. That makes trust, clinical familiarity, and the breadth of evidence important considerations alongside efficacy, safety, and treatment burden. ²

ALPROLIX® (Coagulation Factor IX (Recombinant), Fc Fusion Protein), a recombinant factor IX Fc fusion protein, is an extended half-life factor IX therapy indicated for adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. ALPROLIX carries risks that HCPs should consider when evaluating treatment, including allergic-type hypersensitivity reactions, inhibitor development, thromboembolic complications, and nephrotic syndrome. The most common adverse reactions in previously treated patients were headache, oral paresthesia, and obstructive uropathy. ⁵

As the first FDA-approved EHL factor IX therapy for hemophilia B, ALPROLIX has more than a decade of experience across pediatric and adult populations, including previously-treated and previously-untreated patients.² It has also been studied in more previously-treated children than any other EHL factor IX therapy.

That experience is supported by evidence spanning phase 3 clinical trials, long-term extension studies, and real-world practice. ^2,3,6 Together, these data provide insight into how ALPROLIX has been evaluated not only during initial treatment, but over time — a consideration that can be especially meaningful when selecting therapies for children whose treatment journey may continue through adolescence and adulthood. ²

Evidence Supporting Pediatric and Long-Term Treatment Planning

For HCPs caring for pediatric patients with hemophilia B, treatment decisions often extend beyond immediate bleed prevention to consider how therapy may support patients as they grow and their needs evolve.² ALPROLIX has been evaluated across phase 3 clinical trials, long-term follow-up, and real-world clinical practice, providing a broad body of evidence to help inform these discussions. ^2,3,6

Kids B-LONG was a phase 3 open-label study investigating the safety and efficacy of ALPROLIX in 30 PTPs aged ≤11 years with severe hemophilia. The number of patients 1 to 5 years of age was 15, and 6 to 11 years of age was 15. All 30 patients were treated with ALPROLIX on an individualized prophylactic regimen.⁵

B-LONG was a phase 3 open-label study investigating the safety and efficacy of ALPROLIX in 123 adult and adolescent PTPs with severe hemophilia B. Study arms included: fixed-interval (weekly) (n=63), fixed-dose (interval-adjusted) (n=29), on-demand (n=27), and surgical (n=12).⁵

B-YOND was an open-label extension trial that studied the long-term safety and efficacy of ALPROLIX over 5 years in 120 adult, adolescent, and pediatric patients previously treated in Kids B-LONG or B-LONG. Study arms included: fixed-interval (n=74), fixed-dose (n=36), modified prophylaxis (n=17), and on-demand (n=15).¹⁰

From Evidence to Everyday Care: One Family’s Experience With Hemophilia B

While clinical and long-term follow-up data help inform treatment decisions, patient experiences can show how those decisions may play out over time. For Landon and his mother, Alicia, hemophilia B management has evolved alongside the milestones of childhood and adolescence.

Landon was diagnosed with hemophilia B as an infant after experiencing bleeding complications shortly after birth. After several early bleeding events, including his first joint bleed at 10 months old, his doctors recommended beginning prophylactic factor IX replacement therapy. At the time, Alicia was driving nearly two hours each way to the treatment center for Landon’s twice-weekly infusions.

When Landon was approaching his second birthday, Alicia spoke with his doctor about ALPROLIX. After discussing the benefits and risks, she decided to move forward because she wanted a treatment that would give him more time between infusions and bleed protection.

Landon has now been using ALPROLIX for more than a decade. He started with once-weekly infusions, and later transitioned to once every two weeks.⁵ Over time, he and Alicia have also adapted the way they manage hemophilia together, from finding creative ways to make infusions easier when he was younger to helping him build confidence and independence as he has grown.

Today, Landon enjoys swimming, golfing, and playing guitar. He has also joined a band, performs shows, and participates in teen support groups through the hemophilia community. His experience illustrates how treatment routines, support systems, and personal goals can evolve as a child with hemophilia B grows older.

“I’m thankful ALPROLIX is working for Landon and protecting him against bleeds,” Alicia said. “I have more peace of mind knowing that he has that protection, so that we can focus on doing the things that we love.”

Patient stories reflect the real-life experiences of persons diagnosed with hemophilia B who have been prescribed ALPROLIX. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using ALPROLIX may experience.

Alicia and Landon were compensated by Sanofi for their time sharing their story.

Supporting Patients Through Every Stage of the Journey

Pediatric hemophilia B management requires HCPs to consider the patient in front of them today, as well as the adolescent and young adult that patient may become. As children grow, their treatment needs, daily routines, and level of independence can change, making regular reassessment an important part of care.²

For some families, these conversations may include whether an EHL factor IX therapy can help address treatment burden compared with more frequent SHL regimens. ^3,4 For clinicians, they may also include the depth of evidence supporting long-term use, including clinical trial experience, extension data, and real-world experience. ^2,3,6

As the hemophilia B treatment landscape continues to evolve, maintaining confidence in treatment decisions remains important for HCPs, patients, and caregivers. With more than a decade of experience across ages and settings, ALPROLIX offers an established evidence base across pediatric and adult populations that can help inform treatment planning as patients’ needs evolve.^2,3,6

For HCPs caring for pediatric patients whose treatment journey may span years, that evidence can help inform treatment decisions designed to support continuity of care as patients grow.^1,2

ALPROLIX Indication and Important Safety Information

INDICATION

ALPROLIX is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

• On-demand treatment and control of bleeding episodes
• Perioperative management of bleeding
• Routine prophylaxis to reduce the frequency of bleeding episodes

LIMITATION OF USE:

ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS:

• Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
• Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
• The use of Factor IX products has been associated with the development of thromboembolic complications.
• Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.

ADVERSE REACTIONS:

The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.

Please see Full Prescribing Information

For more information about ALPROLIX visit www.alprolix.com

Sanofi does not provide medical advice, diagnosis, or treatment. The health information contained herein is provided for general educational purposes only. Please consult your healthcare professional if you have any questions about your health or treatment.'

Intended for U.S. Residents Only.

REFERENCES

1. Nolan B, Mahlangu JN, Pasi KJ, et al. Recombinant factor IX Fc fusion protein in previously untreated patients with hemophilia B: results from the PUPs B-LONG study. Blood Adv. 2021;5(13):2730-2738. doi:10.1182/bloodadvances.2020003943
2. Shapiro AD, Kulkarni RD, Ragni MV, et al. Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023;7(13):3049-3057. doi:10.1182/bloodadvances.2022009225
3. Powell JS, Pasi KJ, Ragni MV, et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313-2323. doi:10.1056/NEJMoa1305074
4. Iorio A, Edginton AN, Blanchette VS, et al. Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: rationale and general considerations. Ther Drug Monit. 2017;39(6):593-604. doi:10.1097/FTD.0000000000000451.
5. ALPROLIX. Package insert. Bioverativ Therapeutics Inc.
6. Shapiro A, Chaudhury A, Wang M, et al. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia. 2020;26(6):975-983. doi:10.1111/hae.14108
7. Idelvion. Package insert. CSL Behring GmbH; 2023
8. Rebinyn. Package insert. Novo Nordisk Inc; 2022.
9. Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4(2):e75-e82.
10. Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262-e271

MAT-US-2608625-v1.0-08/2026

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of Sanofi group, except where trademarks are owned by third parties.